US4863899A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active polypeptides
Assignee: Applied Protein Sciences LLC
•
Filing: 1987-05-22
•
Granted: 1989-09-05
•
Expires: 2007-05-22
Abstract
Abstract Novel biologically active polypeptides, including a new class of transforming growth factor (TGF) polypeptides, which exhibit cell growth promoting properties are disclosed, as well as a process for isolating the TGF polypeptides from both human and murine cell lines in homogeneous form. Also disclosed are antigenic oligopeptides derived from the TGF polypeptides and antibodies raised therefrom which have application in the detection and treatment of malignancies and oligipeptides which have the ability to bind with cellular growth factor receptors and thus to interfere with transformation of certain cell lines into a cancerous state. Compositions and methods based on the disclosed peptides for detection and treatment of cancer and other proliferative diseases and for cell or tissue growth associated treatment, e.g., wound healing, ulcer therapy and bone loss are also described.
Inventors
- 👤 George J. Todaro
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 09:52
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/08; C07K14/00; C07K14/435; C07K14/475; C07K14/495; C07K16/00; C07K16/18; C07K16/22; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 82
Claim 1
Independent Claim
127 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR7## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10 and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 2
Independent Claim
127 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR7## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10 and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 3
Dependent Claim
57 words
A composition for treatment of cancer or other proliferative disease which comprises a therapeutic amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR8## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr together with a pharmaceutically acceptable carrier therefor.
Claim 4
Dependent Claim
57 words
A composition for treatment of cancer or other proliferative disease which comprises a therapeutic amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR8## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr together with a pharmaceutically acceptable carrier therefor.
Claim 5
Dependent Claim
115 words
A composition for treatment of tissue damage which comprises an effective amount of a polypeptide containing at least one peptide sequence of formula: ##STR9## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 together with a pharmaceutically acceptable carrier therefor, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 6
Dependent Claim
115 words
A composition for treatment of tissue damage which comprises an effective amount of a polypeptide containing at least one peptide sequence of formula: ##STR9## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 together with a pharmaceutically acceptable carrier therefor, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 7
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR10## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr in a therapeutic amount.
Claim 8
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR10## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr in a therapeutic amount.
Claim 9
Independent Claim
173 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a transforming growth factor polypeptide in a therapeutic amount wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR11## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 10
Independent Claim
173 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a transforming growth factor polypeptide in a therapeutic amount wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR11## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 11
Independent Claim
125 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR12## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 12
Independent Claim
125 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR12## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 13
Independent Claim
140 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR13## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 14
Independent Claim
140 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR13## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 15
Independent Claim
125 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR14## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 16
Independent Claim
125 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR14## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000, and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 17
Independent Claim
140 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR15## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 18
Independent Claim
140 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR15## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 19
Dependent Claim
19 words
The method of claim 5, 6, 7, 8, or 9 wherein the antibody is labeled with a cytotoxic agent.
Claim 20
Independent Claim
53 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide growth factor containing one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala in a therapeutic amount.
Claim 21
Independent Claim
53 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide growth factor containing one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala in a therapeutic amount.
Claim 22
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to an antigeneic polypeptide selected from the sequences consisting of: A. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr in a therapeutic amount.
Claim 23
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to an antigeneic polypeptide selected from the sequences consisting of: A. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr in a therapeutic amount.
Claim 24
Independent Claim
46 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide selected from the sequences consisting of: (1) Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys (2) Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys (3) Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys (4) Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys and (5) Cys-Ser-His-Gly-Tyr-Thr-Gly-Ile-Arg-Cys in a therapeutic amount.
Claim 25
Independent Claim
46 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide selected from the sequences consisting of: (1) Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys (2) Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys (3) Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys (4) Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys and (5) Cys-Ser-His-Gly-Tyr-Thr-Gly-Ile-Arg-Cys in a therapeutic amount.
Claim 26
Dependent Claim
17 words
The method of claim 11, 12, or 13 wherein the antibody is labeled with a cytotoxic agent.
Claim 27
Dependent Claim
19 words
The method of claim 4 wherein R is Asp, R' is Phe, R" is Phe and R'" is Tyr.
Claim 28
Independent Claim
54 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide wherein the polypeptide contains one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Thr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala in a therapeutic amount.
Claim 29
Independent Claim
54 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide wherein the polypeptide contains one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr-Gln-Tyr-Cys-Phe-His-Gly-Thr-Cys B. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr-Gln-Phe-Cys-Phe-His-Gly-Thr-Cys C. Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly D. Cys-His-Ser-Gly-Thr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala E. Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala-Cys-Val-Cys-His-Ser-Gly and F. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala in a therapeutic amount.
Claim 30
Independent Claim
66 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide wherein the polypeptide contains one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Aap-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr in a therapeutic amount.
Claim 31
Independent Claim
66 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide wherein the polypeptide contains one or more of the following peptide sequences: A. Val-Val-Ser-His-Phe-Asn-Aap-Cys-Pro-Asp-His-Thr B. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-His-Thr C. Arg-Phe-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala D. Arg-Tyr-Leu-Val-Gln-Glu-Glu-Lys-Pro-Ala E. Cys-His-Ser-Gly-Phe-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala F. Cys-His-Ser-Gly-Tyr-Val-Gly-Val-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala G. Arg-Phe-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala H. Arg-Tyr-Leu-Val-Gln-Glu-Asp-Lys-Pro-Ala I. Cys-His-Ser-Gly-Phe-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala J. Cys-His-Ser-Gly-Tyr-Val-Gly-Ala-Arg-Cys-Glu-His-Ala-Asp-Leu-Leu-Ala K. Val-Val-Ser-His-Phe-Asn-Asp-Cys-Pro-Asp-Ser-His-Thr and L. Val-Val-Ser-His-Phe-Asn-Lys-Cys-Pro-Asp-Ser-His-Thr in a therapeutic amount.
Claim 32
Dependent Claim
18 words
The method of claim 4, 14, 15 or 16 wherein the antibody is labled with a cytotoxic agent.
Claim 33
Independent Claim
122 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of formula: ##STR16## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 34
Independent Claim
122 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of formula: ##STR16## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 35
Independent Claim
138 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR17## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 36
Independent Claim
138 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide or oligomer thereof of the formula: ##STR17## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 37
Independent Claim
122 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR18## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 38
Independent Claim
122 words
A method for treating a host suspected of having malignant cells which comprises administering to said host an antibody raised to a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR18## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8 in a therapeutic amount, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 39
Dependent Claim
17 words
The method of claim 19, 20, or 21 wherein the antibody is labeled with a cytotoxic agent.
Claim 40
Independent Claim
178 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a transforming growth factor polypeptide wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR19## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 41
Independent Claim
178 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a transforming growth factor polypeptide wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR19## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 42
Independent Claim
129 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR20## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 43
Independent Claim
129 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR20## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 44
Independent Claim
145 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR21## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 45
Independent Claim
145 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR21## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 46
Independent Claim
130 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR22## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 47
Independent Claim
130 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR22## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 48
Independent Claim
144 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of biological active polypeptide or oligomer thereof of the formula: ##STR23## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 49
Independent Claim
144 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of biological active polypeptide or oligomer thereof of the formula: ##STR23## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 50
Independent Claim
66 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR24## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 51
Independent Claim
66 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR24## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 52
Independent Claim
66 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR25## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 53
Independent Claim
66 words
A method for treating or aiding in the treatment of a human host diagnosed as having cancer or other proliferative disease which comprises administering to said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR25## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 54
Independent Claim
127 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide containing at least one sequence of formula: ##STR26## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys -1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 55
Independent Claim
127 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide containing at least one sequence of formula: ##STR26## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys -1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 56
Independent Claim
143 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR27## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 57
Independent Claim
143 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR27## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 58
Independent Claim
128 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR28## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 59
Independent Claim
128 words
A method for treating or aiding in the treatment of a host diagnosed as having cancer or other proliferative disease which comprises administering to said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR28## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 60
Independent Claim
176 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a transforming growth factor polypeptide wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR29## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 61
Independent Claim
176 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a transforming growth factor polypeptide wherein the polypeptide is capable of transforming non-neoplastic cells by causing the: (a) loss of density-dependent inhibition of cell growth in monolayer culture; (b) overgrowth of cells in monolayer culture; (c) change in cellular shape, with the result that the cells assume the neoplastic phenotype; and (d) which contains at least one peptide sequence of formula: ##STR29## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4 and Cys-5 is bonded to Cys-6 through disulfide bonds, the polypeptide is capable of binding to the EGF receptor, and its molecular weight is from about 5,000 to about 35,000.
Claim 62
Independent Claim
143 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR30## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 63
Independent Claim
143 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR30## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 64
Independent Claim
128 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR31## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 65
Independent Claim
128 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR31## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 66
Independent Claim
143 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR32## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 67
Independent Claim
143 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR32## wherein AA is an amino acid residue selected from Val, Ser, Ile, Met, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 68
Independent Claim
64 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR33## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 69
Independent Claim
64 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR33## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 70
Independent Claim
64 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR34## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 71
Independent Claim
64 words
A method of promoting repair of tissue damage in a human host which comprises administering to the locus of said tissue damage in said human host an effective amount of a polypeptide transforming growth factor or oligomer thereof of the formula: ##STR34## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr.
Claim 72
Independent Claim
125 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR35## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 73
Independent Claim
125 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of formula: ##STR35## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4 or 5, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 74
Independent Claim
141 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR36## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 75
Independent Claim
141 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide or oligomer thereof of the formula: ##STR36## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and n is an integer of from 4 to 10, m is 7, o is 4 or 5, p is 10, q is 8 and r is an integer of from 6 to 12, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 76
Independent Claim
126 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR37## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 77
Independent Claim
126 words
A method of promoting repair of tissue damage in a host which comprises administering to the locus of said tissue damage in said host an effective amount of a biologically active polypeptide containing at least one peptide sequence of the formula: ##STR37## wherein AA is an amino acid residue selected from Val, Ser, His, Phe, Ile, Met, Asn, Lys, Asp, Thr, Gln, Arg, Leu, Glu, Pro, Ala, Gly, Trp and Tyr, and a is 7, b is 4, c is 10, and d is 8, wherein the polypeptide is capable of binding to the EGF receptor, has a molecular weight from about 5,000 to about 35,000 and Cys-1 is bonded to Cys-3, Cys-2 is bonded to Cys-4, and Cys-5 is bonded to Cys-6 through disulfide bonds.
Claim 78
Dependent Claim
55 words
A composition for treatment of cancer or other proliferative disease which comprises a therapeutic amount of an antibody raised to a polypeptide of the formula: ##STR38## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr, together with a pharmaceutically acceptable carrier therefor.
Claim 79
Dependent Claim
55 words
A composition for treatment of cancer or other proliferative disease which comprises a therapeutic amount of an antibody raised to a polypeptide of the formula: ##STR38## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr, together with a pharmaceutically acceptable carrier therefor.
Claim 80
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide transforming growth factor or oligomers thereof of the formula: ##STR39## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr in a therapeutic amount.
Claim 81
Independent Claim
61 words
A method for treating a human host suspected of having malignant cells which comprises administering to said human host an antibody raised to a polypeptide transforming growth factor or oligomers thereof of the formula: ##STR39## wherein R is Asp or Lys, R' is Phe or Tyr, R" is Ser or Phe and R'" is Phe or Tyr in a therapeutic amount.
Claim 82
Dependent Claim
14 words
The method of claim 43 wherein the antibody is labeled with a cytotoxic agent.
References Cited (Backward Citations)
US4287185A
Cited
US4428942A
Cited
JPS5921605A
Cited
US4443434A
Cited
WO1984001106A1
Cited
US4485101A
Cited
WO1985002198A1
Cited
EP0154434A1
Cited
US4742003A
Cited
WO1986002650A1
Cited
US4749683A
Cited
EP0190018A2
Cited
US4686283A
Cited
US4650787A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-04 | 1993-03-06 | 1993-09-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-04 | 1997-03-06 | 1997-09-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-04 | 2001-03-06 | 2001-09-05 | $7700.00 | Window Closed / Lapsed |